Printer Friendly

TELECONCEPTS SAYS AIDS TEST MAY IDENTIFY NEW HIV STRAIN

 TELECONCEPTS SAYS AIDS TEST MAY IDENTIFY NEW HIV STRAIN
 HOUSTON, July 21 /PRNewswire/ -- TeleConcepts Corp. (AMEX: TCC)


announced today that the Fluorognost HIV-1 test marketed by its merger partner, Thermascan Inc. (NASDAQ: THEM), may be effective in identifying the new strain of HIV virus which recently published reports have said was not targeted by the traditional EIA screening and WB confirmation tests.
 Thermascan, Inc., today advised the chairman of the 8th International Conference on AIDS, Dr. Jonathan Mann, that an important new technology recently approved by the FDA for testing HIV-1 antibodies in human serum or plasma has not been used to screen the blood of patients diagnosed with AIDS, but reported to be HIV-1 antibody negative. Without including the new immunofluorescence assay (IFA) technology to test these patients, Thermascan suggested that it is unclear if these patients are infected with a new, undetectable strain of the virus, or if other tests simply did not pick up the presence of HIV-1 antibodies.
 This information was offered in response to the recent disclosure by the CDC that 11 patients, including five Americans, have developed full- blown AIDS without testing positive for the HIV-1 virus.
 Fluorognost HIV-1 IFA uses fixed, whole, target T-cells to present a unique set of HIV-1 antigens, and may, therefore, detect HIV-1 antibodies that other tests don't, suggests a spokesman for Thermascan, the U.S. distributor of Fluorognost HIV-1 IFA.
 Fluorognost HIV-1 IFA is licensed by the FDA as a more specific test for HIV-1 antibodies in samples found repeatedly reactive on screening tests, such as ELISA (enzyme-linked immunosorbent assay), and it is licensed as a screening test in hospital laboratories, medical clinics, physicians' offices and emergency care situations and in blood banks or other settings where other tests are not practical or available. Technical training materials are supplied with Fluorognost kits.
 Clinical data show that Fluorognost HIV-1 IFA is equivalent in sensitivity to licensed ELISA tests and equivalent in sensitivity and specificity to licensed WB (Western Blot) tests. Clinical studies also show that the IFA results are rarely indeterminant and may help resolve samples which are indeterminant on WB tests.
 Thermascan informed Mann that they will make Fluorognost HIV-1 IFA test kit available to researchers wishing to test patients diagnosed with AIDS but HIV-1 negative by other tests.
 After the merger with TeleConcepts, expected in mid-August, the Thermascan medical diagnostics business will continue in a new public company, Viral Testing Systems Corporation. TeleConcepts currently designs and markets telephones and telephone devices for residential and commercial use. The telephone business will be spun off to stockholders, after which it will continue as TeleConcepts, Inc. (new symbol: TCX), listed on the American Stock Exchange.
 -0- 7/21/92
 /CONTACT: Detlev Baurs-Krey of Thermascan, 516-287-3739; or Paul Montle of TeleConcepts, 713-228-4633/
 (TCC THEM) CO: TeleConcepts Corp.; Thermascan Inc. ST: Texas IN: MTC SU:


GK-TM -- NY110 -- 1591 07/21/92 17:56 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1992
Words:482
Previous Article:WEIRTON STEEL CORP. ISSUES EARNINGS
Next Article:CEDAR FAIR, L.P. COMPLETES ACQUISITION OF DORNEY PARK AND WILDWATER KINGDOM
Topics:


Related Articles
Improving the AIDS test: genetic engineers offer a new approach to AIDS-antibody testing.
TELECONCEPTS SETS NEW DATE FOR SPECIAL MEETING TO APPROVE MERGER
TELECONCEPTS RECEIVES FIRM COMMITMENTS FOR EQUITY PLACEMENT IN EXCESS OF MINIMUM REQUIRED FOR MERGER WITH THERMASCAN, INC.
TELECONCEPTS TO MARKET THE FIRST ALL-HUMAN LINE OF MONOCLONAL ANTIBODY REAGENTS TO THE AIDS VIRUS
THERMASCAN STATEMENT ON UNRESOLVED HIV-1 ANTIBODY STATUS
THE JOURNAL OF CLINICAL MICROBIOLOGY REPORTS THAT A NEW FDA-APPROVED AIDS TEST WILL IMPROVE SPECIFICITY OF HIV CONFIRMATORY TESTING
THERMASCAN STOCKHOLDERS APPROVE MERGER WITH TELECONCEPTS
VIRAL TESTING SYSTEMS ANNOUNCES SALE OF ITS TELEPHONE BUSINESS
Visible Genetics Inc. Acquires Privately Held Applied Sciences, Inc., An Atlanta-Based Diagnostics Company Specializing in HIV Genotyping
Medical Services to Supply Law Enforcement Agencies With HIV Test Kits.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters